Studies

BxChip™ Clinical Tissue Array Increases Cancer Detection Rate & Amount of Tissue Available for Pathologist Review

Kirk Wojno*, Royal Oak, MI; Rima Al-Jundi, St. Clair Shores, MI; Ann Mazurco, Royal Oak, MI; Hayder Al Hamzawy, Salt Lake, UT

INTRODUCTION AND OBJECTIVES: Due to significant cuts in reimbursement, more efficient histology techniques are needed to maintain the economic viability of the histology laboratory. There is also an increasing need to maximize tissue preservation for ancillary testing. The BxChipTM(Leavitt Medical Inc. Patent Pending) is a clinical tissue array made of an artificial tissue-like material which easily receives and holds multiple tissue cores. Encasing numerous needle cores, enables the arrayed samples to be processed, embedded and sectioned as though they were a single standard tissue. Colored dividers between each core allow the pathologist to distinguish different anatomic sites, while providing orientation of each core. The purpose of this study is to compare the overall prostate cancer detection rates and the average amount of tissue present (average area and core-length) on normal slides versus those made with BxChip clinical tissue arrays.

METHODS: 267 consecutive twelve pack prostate needle biopsies were analyzed during a 5 week period. Approximately half of the cases were processed and embedded using the BxChip clinical tissue array and the other cases were done with conventional blocks and slides. The cases were matched according to the urologist performing the procedure in order to account for biopsy technique. Slide tissue measurements were performed using a Leica SCN 400 scanner, and images were stored, sorted and measured using DIH software (Leica).

RESULTS: Comparing traditional sectioning to CHIP based sectioning the cross sectional surface area of tissue on the glass slide available for review and length of biopsy tissue on the slide increased from an average of 4.8 mm2 and 10.7 mm to 5.5 mm2 and 14.1 mm respectively. This was significant at a level of p<0.0001 The cancer detection rate increased from 49.5% to 58.8% comparing traditional sectioning to Chip based sectioning p<0.0001 Current diagnostic molecular techniques have been validated on this platform.

CONCLUSIONS: Superior prostate biopsy performance is achieved by utilizing the BxChip clinical tissue arrays. Additionally, this comes with tremendous cost savings to the laboratory.

Source of Funding: None

Originally Published in The Journal of Urology®

Wojno K, Al-Jundi R, Mazurco A, Hamzawy HA. Mp 16-19 BxChip™ Clinical tissue array increases cancer detection rate & amount of tissue available for pathologist review.  The Journal of Urology. 2016; 195(4). doi:10.1016/j.juro.2016.02.2584

LUMEA’s BxChip™

Prostate Biopsy Processing

An Innovative Model for Reducing Cost, Decreasing Test Time, and Improving Diagnostic Material

Originally Published in The American Journal of Clinical Pathology©

Murugan P, Shukla D, Morocho J, Smith D, Sciacca D, Pickard M, Wahlsten M, Gunderson A, Konety B, Khalifa MA, Warlick C. Prostate Biopsy Processing: An Innovative Model for Reducing Cost, Decreasing Test Time, and Improving Diagnostic Material, American Journal of Clinical Pathology, Volume 152, Issue 6, December 2019, Pages 757-756